Although, SMZL with plasmocytic differentiation and LPL/WM both have abnormal lymphocytes and monoclonal plasmacytes in the FCM analysis of bone marrow, research had shown that the level of CD138 expression in the bone marrow of patients with LPL/WM was dramatically higher than that of patients with SMZL.[8] In addition, the significantly higher expression level of CD180 in SMZL patients compared to LPL/WM was expected to be a specific positive marker for SMZL.[9] In molecular biology, MYD88L265P mutation was in 6% to 21% of patients with SMZL and in over 90% of LPL/WM patients. This evidence concerns the gene SDC1 and splenic marginal zone lymphoma.